Skip to main
IMRX
IMRX logo

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering Corp demonstrates a positive outlook due to significant improvements in overall survival (OS) and progression-free survival (PFS) rates over current standard of care (SoC), which positions the company favorably in the competitive biopharmaceutical landscape. Furthermore, the safety data recorded shows enhancements in tolerability for atebimetinib compared to existing therapies and therapies in development, supporting the notion of a strong efficacy-tolerability balance. Lastly, the evidence of superior safety with potentially lower median PFS compared to another treatment option reinforces the therapeutic potential of Immuneering's offerings and enhances investor confidence in the company's future.

Bears say

Immuneering Corp faces a negative outlook primarily due to the higher rates of anemia observed in its studies, which could raise concerns about the safety and efficacy of its drug candidates. The implications of these adverse effects may hinder the company’s progress in clinical trials, potentially affecting future product approvals and market potential. Furthermore, the recurring mention of anemia raises red flags regarding the overall risk profile of Immuneering’s therapies, which could adversely impact investor confidence and valuations.

Immuneering Corp (IMRX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immuneering Corp (IMRX) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.